CTA Filing in Late December 2010 Represented the Eighth Clinical Milestone Last Year
MARTINSRIED, GERMANY and MUNCHEN, GERMANY | January 24, 2011 | MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has received a clinical milestone payment from Boehringer Ingelheim in connection with the regulatory filing of a clinical trial application for a phase 1 trial of a HuCAL-derived antibody. The filing took place in late December 2010 making this the eighth clinical milestone met with partners during the year. Financial details are not disclosed.
"In 2010, we saw eight clinical milestones reached with five different partners which surpassed our original expectations for the year of up to six such events," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Today’s news marks the start of the first clinical program within our partnership with Boehringer Ingelheim."
MorphoSys’s clinical pipeline now comprises ten partnered programs in Phase 1 and five in Phase 2 development as well as the Company’s proprietary programs MOR103, which is in a Phase 1b/2a trial for rheumatoid arthritis, and MOR208, which is in a Phase 1 trial for chronic lymphocytic leukemia.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company’s HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world’s leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM- CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visithttp://www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys; arYla™ is a trademark of MorphoSys.
SOURCE: MorphoSys AG
Post Views: 36
CTA Filing in Late December 2010 Represented the Eighth Clinical Milestone Last Year
MARTINSRIED, GERMANY and MUNCHEN, GERMANY | January 24, 2011 | MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that it has received a clinical milestone payment from Boehringer Ingelheim in connection with the regulatory filing of a clinical trial application for a phase 1 trial of a HuCAL-derived antibody. The filing took place in late December 2010 making this the eighth clinical milestone met with partners during the year. Financial details are not disclosed.
"In 2010, we saw eight clinical milestones reached with five different partners which surpassed our original expectations for the year of up to six such events," commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG. "Today’s news marks the start of the first clinical program within our partnership with Boehringer Ingelheim."
MorphoSys’s clinical pipeline now comprises ten partnered programs in Phase 1 and five in Phase 2 development as well as the Company’s proprietary programs MOR103, which is in a Phase 1b/2a trial for rheumatoid arthritis, and MOR208, which is in a Phase 1 trial for chronic lymphocytic leukemia.
About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company’s HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world’s leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM- CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visithttp://www.morphosys.com/
HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys; arYla™ is a trademark of MorphoSys.
SOURCE: MorphoSys AG
Post Views: 36
